First Header Logo Second Header Logo

Connection

Barry Freedman to Lipoproteins, HDL

This is a "connection" page, showing publications Barry Freedman has written about Lipoproteins, HDL.
Connection Strength

13.983
  1. McLean NO, Robinson TW, Freedman BI. APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter. Am J Kidney Dis. 2017 Aug; 70(2):281-289.
    View in: PubMed
    Score: 0.497
  2. Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. J Am Soc Nephrol. 2017 Apr; 28(4):1093-1105.
    View in: PubMed
    Score: 0.489
  3. Robinson TW, Freedman BI. The Apolipoprotein L1 Gene and Cardiovascular Disease. Methodist Debakey Cardiovasc J. 2016 Oct-Dec; 12(4 Suppl):2-5.
    View in: PubMed
    Score: 0.485
  4. Freedman BI, Gadegbeku CA, Bryan RN, Palmer ND, Hicks PJ, Ma L, Rocco MV, Smith SC, Xu J, Whitlow CT, Wagner BC, Langefeld CD, Hawfield AT, Bates JT, Lerner AJ, Raj DS, Sadaghiani MS, Toto RD, Wright JT, Bowden DW, Williamson JD, Sink KM, Maldjian JA, Pajewski NM, Divers J. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney Int. 2016 08; 90(2):440-449.
    View in: PubMed
    Score: 0.476
  5. Ma L, Langefeld CD, Comeau ME, Bonomo JA, Rocco MV, Burkart JM, Divers J, Palmer ND, Hicks PJ, Bowden DW, Lea JP, Krisher JO, Clay MJ, Freedman BI. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease. Kidney Int. 2016 08; 90(2):389-395.
    View in: PubMed
    Score: 0.472
  6. Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J. APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation. 2016 Jan; 100(1):194-202.
    View in: PubMed
    Score: 0.461
  7. Gutiérrez OM, Judd SE, Irvin MR, Zhi D, Limdi N, Palmer ND, Rich SS, Sale MM, Freedman BI. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrol Dial Transplant. 2016 04; 31(4):602-8.
    View in: PubMed
    Score: 0.445
  8. Freedman BI. APOL1 and kidney disease: new insights leading to novel therapies. Am J Kidney Dis. 2015 Jul; 66(1):9-11.
    View in: PubMed
    Score: 0.445
  9. Freedman BI, Julian BA. Should kidney donors be genotyped for APOL1 risk alleles? Kidney Int. 2015 Apr; 87(4):671-3.
    View in: PubMed
    Score: 0.437
  10. Larsen CP, Freedman BI. Apolipoprotein L1-associated nephropathy and the future of renal diagnostics. J Am Soc Nephrol. 2015 Jun; 26(6):1232-5.
    View in: PubMed
    Score: 0.431
  11. Palmer ND, Ng MC, Langefeld CD, Divers J, Lea JP, Okusa MD, Kimberly RP, Bowden DW, Freedman BI. Lack of Association of the APOL1 G3 Haplotype in African Americans with ESRD. J Am Soc Nephrol. 2015 May; 26(5):1021-5.
    View in: PubMed
    Score: 0.422
  12. Larsen CP, Beggs ML, Saeed M, Ambruzs JM, Cossey LN, Messias NC, Walker PD, Freedman BI. Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Mod Pathol. 2015 Jan; 28(1):95-102.
    View in: PubMed
    Score: 0.418
  13. Freedman BI, Langefeld CD, Lu L, Palmer ND, Smith SC, Bagwell BM, Hicks PJ, Xu J, Wagenknecht LE, Raffield LM, Register TC, Carr JJ, Bowden DW, Divers J. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015 Jan; 87(1):176-81.
    View in: PubMed
    Score: 0.417
  14. Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, Saleem MA, Satchell SC, Banas B, Mathieson PW, Kretzler M, Hemal AK, Rudel LL, Petrovic S, Weckerle A, Pollak MR, Ross MD, Parks JS, Freedman BI. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol. 2015 Feb; 26(2):339-48.
    View in: PubMed
    Score: 0.416
  15. Freedman BI, Skorecki K. Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol. 2014 Nov 07; 9(11):2006-13.
    View in: PubMed
    Score: 0.413
  16. Freedman BI, Divers J, High KP. The authors reply:. Kidney Int. 2014 May; 85(5):1242-3.
    View in: PubMed
    Score: 0.410
  17. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014 Feb; 66(2):390-6.
    View in: PubMed
    Score: 0.404
  18. Divers J, Palmer ND, Lu L, Langefeld CD, Rocco MV, Hicks PJ, Murea M, Ma L, Bowden DW, Freedman BI. Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant. 2014 Mar; 29(3):587-94.
    View in: PubMed
    Score: 0.396
  19. Freedman BI. APOL1 and nephropathy progression in populations of African ancestry. Semin Nephrol. 2013 Sep; 33(5):425-32.
    View in: PubMed
    Score: 0.392
  20. Palmer ND, Freedman BI. APOL1 and progression of nondiabetic nephropathy. J Am Soc Nephrol. 2013 Sep; 24(9):1344-6.
    View in: PubMed
    Score: 0.387
  21. Palanisamy A, Reeves-Daniel AM, Freedman BI. The impact of APOL1, CAV1, and ABCB1 gene variants on outcomes in kidney transplantation: donor and recipient effects. Pediatr Nephrol. 2014 Sep; 29(9):1485-92.
    View in: PubMed
    Score: 0.386
  22. Divers J, Núñez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int. 2013 Dec; 84(6):1207-13.
    View in: PubMed
    Score: 0.384
  23. Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int. 2012 Oct; 82(7):805-11.
    View in: PubMed
    Score: 0.360
  24. Freedman BI, Langefeld CD. The new era of APOL1-associated glomerulosclerosis. Nephrol Dial Transplant. 2012 Apr; 27(4):1288-91.
    View in: PubMed
    Score: 0.351
  25. Freedman BI, Murea M. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep. 2012 Feb; 14(1):21-8.
    View in: PubMed
    Score: 0.351
  26. Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J, Antinozzi PA, Divers J, Hicks PJ, Bowden DW, Rocco MV, Parks JS. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant. 2011 Nov; 26(11):3805-10.
    View in: PubMed
    Score: 0.342
  27. Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW, Freedman BI. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. Kidney Int. 2011 Dec; 80(12):1339-43.
    View in: PubMed
    Score: 0.340
  28. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, Winkler CA, Nelson GW, Johnson RC, Palmer ND, Hicks PJ, Bostrom MA, Cooke JN, McDonough CW, Bowden DW. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 2011 Jun; 7(6):e1002150.
    View in: PubMed
    Score: 0.336
  29. Freedman BI, Sedor JR. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 12 23; 363(26):2565; author reply 2565-6.
    View in: PubMed
    Score: 0.325
  30. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010 Sep; 21(9):1422-6.
    View in: PubMed
    Score: 0.317
  31. Divers J, Freedman BI. Response to Comment on Chan et al. FGF23 Concentration and APOL1 Genotype Are Novel Predictors of Mortality in African Americans With Type 2 Diabetes. Diabetes Care 2018;41:178-186. Diabetes Care. 2018 05; 41(5):e79-e80.
    View in: PubMed
    Score: 0.135
  32. Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J. A tripartite complex of suPAR, APOL1 risk variants and avß3 integrin on podocytes mediates chronic kidney disease. Nat Med. 2017 Aug; 23(8):945-953.
    View in: PubMed
    Score: 0.128
  33. Robinson TW, Freedman BI. APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy. Kidney Int. 2017 02; 91(2):276-278.
    View in: PubMed
    Score: 0.124
  34. Dorr CR, Freedman BI, Hicks PJ, Brown WM, Russell GB, Julian BA, Pastan SO, Gautreaux MD, Muthusamy A, Chinnakotla S, Hauptfeld V, Bray RA, Kirk AD, Divers J, Israni AK. Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes. PLoS One. 2016; 11(4):e0152775.
    View in: PubMed
    Score: 0.117
  35. Weckerle A, Snipes JA, Cheng D, Gebre AK, Reisz JA, Murea M, Shelness GS, Hawkins GA, Furdui CM, Freedman BI, Parks JS, Ma L. Characterization of circulating APOL1 protein complexes in African Americans. J Lipid Res. 2016 Jan; 57(1):120-30.
    View in: PubMed
    Score: 0.114
  36. Hawkins GA, Friedman DJ, Lu L, McWilliams DR, Chou JW, Sajuthi S, Divers J, Parekh RS, Li M, Genovese G, Pollack MR, Hicks PJ, Bowden DW, Ma L, Freedman BI, Langefeld CD. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression. Am J Nephrol. 2015; 42(2):99-106.
    View in: PubMed
    Score: 0.113
  37. Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, Freedman BI, Parks JS, Shelness GS. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J Lipid Res. 2015 Aug; 56(8):1583-93.
    View in: PubMed
    Score: 0.111
  38. Bentley AR, Divers J, Shriner D, Doumatey AP, Gutiérrez OM, Adeyemo AA, Freedman BI, Rotimi CN. APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics. 2015 May 30; 16:421.
    View in: PubMed
    Score: 0.111
  39. Ma J, Divers J, Palmer ND, Julian BA, Israni AK, Schladt D, Pastan SO, Chattrabhuti K, Gautreaux MD, Hauptfeld V, Bray RA, Kirk AD, Brown WM, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Guan M, Palanisamy A, Reeves-Daniel AM, Bowden DW, Langefeld CD, Hicks PJ, Ma L, Freedman BI. Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation. Kidney Int. 2015 Sep; 88(3):584-92.
    View in: PubMed
    Score: 0.110
  40. Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE, Kaysen GA, Kimmel PL, Raj DS, Ricardo AC, Wright JT, Sedor JR, Rocco MV, Freedman BI. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015 Jan; 87(1):169-75.
    View in: PubMed
    Score: 0.104
  41. Palmer ND, Ng MC, Hicks PJ, Mudgal P, Langefeld CD, Freedman BI, Bowden DW. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One. 2014; 9(2):e88273.
    View in: PubMed
    Score: 0.101
  42. Bailey JNC, Palmer ND, Ng MCY, Bonomo JA, Hicks PJ, Hester JM, Langefeld CD, Freedman BI, Bowden DW. Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans. Hum Genet. 2014 Jun; 133(6):769-779.
    View in: PubMed
    Score: 0.100
  43. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013 Dec 05; 369(23):2183-96.
    View in: PubMed
    Score: 0.099
  44. Palmer ND, Freedman BI. Insights into the genetic architecture of diabetic nephropathy. Curr Diab Rep. 2012 Aug; 12(4):423-31.
    View in: PubMed
    Score: 0.091
  45. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013 Jan; 83(1):114-20.
    View in: PubMed
    Score: 0.091
  46. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010 Aug 13; 329(5993):841-5.
    View in: PubMed
    Score: 0.079
  47. Bonomo JA, Ng MC, Palmer ND, Keaton JM, Larsen CP, Hicks PJ, Langefeld CD, Freedman BI, Bowden DW. Coding variants in nephrin (NPHS1) and susceptibility to nephropathy in African Americans. Clin J Am Soc Nephrol. 2014 Aug 07; 9(8):1434-40.
    View in: PubMed
    Score: 0.026
  48. Bostrom MA, Kao WH, Li M, Abboud HE, Adler SG, Iyengar SK, Kimmel PL, Hanson RL, Nicholas SB, Rasooly RS, Sedor JR, Coresh J, Kohn OF, Leehey DJ, Thornley-Brown D, Bottinger EP, Lipkowitz MS, Meoni LA, Klag MJ, Lu L, Hicks PJ, Langefeld CD, Parekh RS, Bowden DW, Freedman BI. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy. Am J Kidney Dis. 2012 Feb; 59(2):210-21.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.